co-dx

Co-Diagnostics, Inc. Makes Strategic Additions to Scientific Advisory Board

Co-Diagnostics, Inc. Makes Strategic Additions to Scientific Advisory Board
Co-Diagnostics, Inc. Announces Authorization of $30 Million Share Repurchase Program

Co-Diagnostics announced that its Board of Directors has authorized a share repurchase program that would allow the Company…
Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Hepatitis B Viral Load Test

SALT LAKE CITY, Feb. 3, 2022 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), a molecular diagnostics company with…
Co-Diagnostics, Inc. to Host Booth at Life Sciences Day on the Hill on February 16 at the Utah State Capital

Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development…
Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for High-Risk HPV Multiplex Test

Co-Diagnostics, Inc. announced that CoSara Diagnostics Pvt Ltd has received clearance by the Central Drugs Standard Control Organization (“CDSCO”)…
Co-Diagnostics, Inc. Signs Agreement to Acquire all Assets and Intellectual Property Related to At-Home/Point-of-Care Platform

Definitive merger agreements provide the Company with all existing and future assets, future product iterations, and intellectual property…
Co-Diagnostics JV CoSara Receives Clearance from Indian Regulators for ABC Multiplex Test

Co-Diagnostics announced that CoSara Diagnostics Pvt Ltd has received clearance by the Central Drugs Standard Control Organization (CDSCO)…
Co-Diagnostics, Inc. Reports that Suite of COVID-19 Diagnostics Not Affected by Heavily Mutated Omicron Variant

None of the mutations in the Omicron variant interfere with any of the Company’s COVID-19 PCR diagnostic assays
Co-Diagnostics Reports Continued Strength in Third Quarter 2021 Financial Results

Solid quarterly results highlighted by record revenue of $30.1 million, pre-tax income of $13.6 million and fully diluted…
Co-Diagnostics, Inc. Logix Smart™ COVID-19 2-Gene Test Approved for Use in the United Kingdom

Company’s validated test available in the UK following implementation of UKHSA CTDA Regulations
Co-Diagnostics, Inc. to Introduce At Home/Point of Care Device at AACC on Sept 28

In addition to hosting a booth to promote its existing diagnostics products at the conference, the Company will…

Call to Action

Experience Seamless Style and Speed

Explore More

Co-Diagnostics, Inc. Makes Strategic Additions to Scientific Advisory Board

Co-Diagnostics, Inc. Announces Authorization of $30 Million Share Repurchase Program

Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Hepatitis B Viral Load Test

Co-Diagnostics, Inc. to Host Booth at Life Sciences Day on the Hill on February 16 at the Utah State Capital

Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for High-Risk HPV Multiplex Test

Co-Diagnostics, Inc. Signs Agreement to Acquire all Assets and Intellectual Property Related to At-Home/Point-of-Care Platform

Co-Diagnostics JV CoSara Receives Clearance from Indian Regulators for ABC Multiplex Test

Co-Diagnostics, Inc. Reports that Suite of COVID-19 Diagnostics Not Affected by Heavily Mutated Omicron Variant

Co-Diagnostics Reports Continued Strength in Third Quarter 2021 Financial Results

Co-Diagnostics, Inc. Logix Smart™ COVID-19 2-Gene Test Approved for Use in the United Kingdom

Co-Diagnostics, Inc. to Introduce At Home/Point of Care Device at AACC on Sept 28

Call to Action

Post Category

Latest Posts

Social Links

SPECIAL THANKS TO OUR LEGACY & PLATINUM ELITE MEMBERS